The Association of Clinical Research Professionals

Webinar: Part 2: iRECIST Workshop

Event Date: April 1, 2020, 12:00-1:00 PM ET

Registration Deadline: March 31, 2020 11:59 PM ET

Speaker:

  • Mary Ricker, MA, RN – Sr. Clinical Research Associate – US Oncology, Merck Research Laboratories

Pricing With Contact Hours

Member: $15 | Nonmember: $75

Add to Cart

This course is approved for 1.0 ACRP contact hours. Accreditation Details


Pricing Without Contact Hours

Member: $0 | Nonmember: N/A

Add to Cart


In oncology clinical trials, assessment of changes in tumor burden is a primary endpoint. For solid tumors, RECIST 1.1 is the established criteria. However, as we move from chemotherapeutic trials into immunotherapeutic trials, a new response to treatment pattern has become evident. A subset of patients to have increased tumor burden that is followed by a clear response or prolonged stabilization of the cancer. iRECIST guidelines have been developed to capture this new response pattern.Part 1 of 2 presentations introduced you to the history of the iRECIST guidelines, the iRECIST process and how iRECIST is being used in oncology clinical trials. This Webinar, Part 2, will consist of a workshop using hypothetical cases to determine iRECIST responses.

Upon completion of this webinar, attendees will be able to:

  1. Understand the history and need for development of the iRECIST guidelines
  2. Define terms of tumor measurement and objective change in tumor burden in iRECIST
  3. Review hypothetical cases to determine iRECIST response